RxDoctor Payments Data

Sara Goel, DO

Pain Medicine · Houston, TXNPI 1023244431

Payments from drug & device makers

$14,581in general payments, 2019–2025

Across 297 payments — averaging $49.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Boston Scientific$2K
  • Nevro Corp.$2K
  • SPR Therapeutics, Inc$2K
  • Relievant Medsystems, Inc.$778
  • Abbott$521
  • plus $4K from 38 others

What the payments were for

  • Travel & lodging$3,64925%
  • Food & beverage$10,93275%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,581 in reported general payments places this provider in the 80th percentile of 583 pain medicine providers in Texas.

See all pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$78,784
Medicare patients
93
Services billed
687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl48$39,091
Nucynta ErTapentadol Hcl17$25,259
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen500$16,181
Aimovig AutoinjectorErenumab-Aooe18$13,557
Buprenorphine45$13,515
SymproicNaldemedine Tosylate11$5,124
Pregabalin160$2,809
Gabapentin246$2,267
Tramadol Hcl ErTramadol Hcl41$1,994
Methocarbamol148$1,878
Fentanyl14$1,717
Morphine Sulfate ErMorphine Sulfate56$1,612
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen63$1,605
Oxycodone Hcl42$1,604
Lidocaine28$1,338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta Er$376$64,35065 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 583 pain medicine providers in Texas.

Other pain medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →